|AHFS/Drugs.com||International Drug Names|
|Chemical and physical data|
|Molar mass||327.33 g/mol|
|3D model (Jmol)||Interactive image|
Tranilast (INN, brand name Rizaben) is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
It is relatively safe and well tolerated by most patients at doses of up to 600 mg/day for months.
After promising results in three small trial Tranilast was studied in a major clinical trial (the PRESTO trial) for prevention of restenosis after percutaneous transluminal coronary revascularization, but was not found effective for that application.
- http://www.jstage.jst.go.jp/article/tjem/217/3/217_193/_article "Tranilast, an Anti-Allergic Drug, Down-Regulates the Growth of Cultured Neurofibroma Cells Derived from Neurofibromatosis Type 1" 2009
- http://molpharm.aspetjournals.org/content/62/4/856.full "Tranilast Inhibits Cytokine-Induced Nuclear Factor κB Activation in Vascular Endothelial Cells" 2002
- http://www.circ.ahajournals.org/cgi/content/full/106/10/1243 "Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial" 2002
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|